研究目的
To evaluate the effect of ranibizumab on retinal circulation times and vessel caliber and to analyze the correlation of these factors with visual acuity (VA) prognosis in patients with age-related macular degeneration (AMD).
研究成果
Ranibizumab treatment is associated with a decrease in retinal arteriolar diameter, central macular thickness, and significant improvement in visual acuity recovery in patients with AMD. Pretreatment larger retinal vessels and more prominent reductions in DRA and CMT after therapy are indicative of a more favorable VA prognosis.
研究不足
The study's limitations include the relatively small sample size and the short follow-up period after the last injection. Further larger prospective studies with longer follow-up are needed to confirm the findings.
1：Experimental Design and Method Selection:
Prospective cohort study including 52 eyes of 46 patients with AMD. Parameters measured were best-corrected visual acuity (BCVA), central macular thickness (CMT), retinal circulation times, diameter of retinal arteriole (DRA), and diameter of retinal vein (DRV).
2：Sample Selection and Data Sources:
Patients with newly diagnosed neovascular AMD, aged 50 years or more, with specific lesion characteristics.
3：List of Experimental Equipment and Materials:
Heidelberg Retinal Angiogram-2 (HRA-2) for fluorescein angiography, Stratus OCT instrument for OCT images, ranibizumab (Lucentis) for injections.
4：Experimental Procedures and Operational Workflow:
Patients received a loading dose of three consecutive injections of ranibizumab at 4-week intervals. Follow-up included monthly clinical and OCT examinations. Retreatment was performed as needed based on specific criteria.
5：Data Analysis Methods:
Statistical analysis using SPSS software, including t-tests, Pearson's correlation test, and logistic regression.
独家科研数据包，助您复现前沿成果，加速创新突破
获取完整内容
